MedDataX Logo

Post-marketing Surveillance Study With MicardisPlus® in Treatment of Morning Hypertension (Self-monitored by Patient)

NCT ID: NCT02243566

Last Updated: 2014-09-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2707 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study was to examine the effect of six- to eight-week treatment with MicardisPlus® on blood pressure and the effect of patient self-monitoring on blood pressure control. In addition, the post-marketing surveillance study offered the possibility to obtain information about the influence on different laboratory parameters during treatment with MicardisPlus® from an unselected patient group under office conditions

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Post-Marketing Surveillance Study of Micardis® Plus in Patients With Hypertension

NCT02238275

Hypertension
COMPLETED

Study to Evaluate Efficacy and Tolerability of Micardis®/Micardis® Plus in Patients With Hypertension

NCT02242357

Hypertension
COMPLETED

Study to Evaluate the Effect of the Treatment With Micardis® or MicardisPlus® on Blood Pressure

NCT02242864

Hypertension
COMPLETED

Study to Evaluate the Effect of Micardis® / MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes Mellitus

NCT02242825

Hypertension
COMPLETED

Evaluation of Efficacy and Tolerability of Micardis® / MicardisPlus® Under Usual Daily-practice Prescribing in Patients With Hypertension

NCT02242383

Hypertension
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Essential hypertension

MicardisPlus®

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MicardisPlus®

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Telmisartan in combination with hydrochlorothiazide

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18 years
* Hypertension

Exclusion Criteria

* Age \< 18 years
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

502.513

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study of a Hypertensive Population Under Treatment With Micardis® and Micardis Plus® to Control the Early Morning BP Rise (SURGE II)
NCT02242396 COMPLETED
Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential Hypertension
NCT02245464 COMPLETED
Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)
NCT02262611 COMPLETED
Micardis® in Patients With Essential Hypertension
NCT02187705 COMPLETED
Additional Effect of A Life Style Program on Antihypertensive Treatment With Telmisartan
NCT01108796 COMPLETED
An Observational Cohort Study to Evaluate the Safety and Efficacy of Micardis Tablets Taken Once Daily at 40 mg/Day and 80 mg/Day in Hypertensive Patients Under Real Life Conditions in Usual Clinical Practice
NCT00982735 COMPLETED
Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension
NCT02242838 COMPLETED
Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients
NCT00879411 COMPLETED
Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise
NCT00946829 COMPLETED
Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)
NCT02262637 COMPLETED
Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension
NCT02242370 COMPLETED PHASE4
PRO-POWER: Hypertension With Risk Factors for a Duration of 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg
NCT00936208 COMPLETED
Nice Morning- Safety and Efficacy Observational Study of Telmisartan in Hypertensive Patients in Multicenters
NCT00615108 COMPLETED
A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients
NCT06174766 RECRUITING PHASE3
Essential Hypertension
NCT01264692 COMPLETED PHASE2
Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension
NCT00257491 COMPLETED PHASE3
Telmisartan+HCTZ (Hydrochlorothiazide), Hypertension
NCT00659607 COMPLETED
A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension
NCT00635232 COMPLETED PHASE2
Assessment of Compliance With Antihypertensive Telmisartan Therapy
NCT00470886 COMPLETED
A Study of Single Dose MK-3614 (MK-3614-001)(COMPLETED)
NCT01104545 COMPLETED PHASE1
Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients
NCT02853045 COMPLETED PHASE4
MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension
NCT00888355 COMPLETED PHASE3
Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients
NCT00904371 COMPLETED
Evaluation of the Safety, Efficacy and Pharmacokinetics of MICARDIS® (Telmisartan) in Children and Adolescents With Hypertension
NCT02242344 COMPLETED PHASE2
Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension
NCT01193101 COMPLETED PHASE2